1
|
Coutant F, Sanchez David RY, Félix T, Boulay A, Caleechurn L, Souque P, Thouvenot C, Bourgouin C, Beignon AS, Charneau P. A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria. PLoS One 2012; 7:e48644. [PMID: 23133649 PMCID: PMC3487763 DOI: 10.1371/journal.pone.0048644] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2012] [Accepted: 09/27/2012] [Indexed: 01/06/2023] Open
Abstract
Trials testing the RTS,S candidate malaria vaccine and radiation-attenuated sporozoites (RAS) have shown that protective immunity against malaria can be induced and that an effective vaccine is not out of reach. However, longer-term protection and higher protection rates are required to eradicate malaria from the endemic regions. It implies that there is still a need to explore new vaccine strategies. Lentiviral vectors are very potent at inducing strong immunological memory. However their integrative status challenges their safety profile. Eliminating the integration step obviates the risk of insertional oncogenesis. Providing they confer sterile immunity, nonintegrative lentiviral vectors (NILV) hold promise as mass pediatric vaccine by meeting high safety standards. In this study, we have assessed the protective efficacy of NILV against malaria in a robust pre-clinical model. Mice were immunized with NILV encoding Plasmodium yoelii Circumsporozoite Protein (Py CSP) and challenged with sporozoites one month later. In two independent protective efficacy studies, 50% (37.5-62.5) of the animals were fully protected (p = 0.0072 and p = 0.0008 respectively when compared to naive mice). The remaining mice with detectable parasitized red blood cells exhibited a prolonged patency and reduced parasitemia. Moreover, protection was long-lasting with 42.8% sterile protection six months after the last immunization (p = 0.0042). Post-challenge CD8+ T cells to CSP, in contrast to anti-CSP antibodies, were associated with protection (r = -0.6615 and p = 0.0004 between the frequency of IFN-g secreting specific T cells in spleen and parasitemia). However, while NILV and RAS immunizations elicited comparable immunity to CSP, only RAS conferred 100% of sterile protection. Given that a better protection can be anticipated from a multi-antigen vaccine and an optimized vector design, NILV appear as a promising malaria vaccine.
Collapse
Affiliation(s)
- Frédéric Coutant
- Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France
| | - Raul Yusef Sanchez David
- Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France
| | - Tristan Félix
- Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France
| | - Aude Boulay
- Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France
| | - Laxmee Caleechurn
- Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France
| | - Philippe Souque
- Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France
| | - Catherine Thouvenot
- Centre de Production et d’Infection des Anophèles (CEPIA), Department of Parasitology and Mycology, Institut Pasteur, Paris, France
| | - Catherine Bourgouin
- Centre de Production et d’Infection des Anophèles (CEPIA), Department of Parasitology and Mycology, Institut Pasteur, Paris, France
| | - Anne-Sophie Beignon
- Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France
| | - Pierre Charneau
- Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France
| |
Collapse
|
2
|
Houben D, Demangel C, van Ingen J, Perez J, Baldeón L, Abdallah AM, Caleechurn L, Bottai D, van Zon M, de Punder K, van der Laan T, Kant A, Bossers‐de Vries R, Willemsen P, Bitter W, van Soolingen D, Brosch R, van der Wel N, Peters PJ. ESX‐1‐mediated translocation to the cytosol controls virulence of mycobacteria. Cell Microbiol 2012; 14:1287-98. [DOI: 10.1111/j.1462-5822.2012.01799.x] [Citation(s) in RCA: 298] [Impact Index Per Article: 24.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Diane Houben
- Division of Cell Biology II, Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital (NKI‐AVL), 1066 CX Amsterdam, the Netherlands
| | - Caroline Demangel
- Institut Pasteur Pathogénomique Mycobactérienne Intégrée, 25 Rue du Docteur Roux, 75724 Paris, France
| | - Jakko van Ingen
- National Tuberculosis Reference Laboratory, National Institute of Public Health and the Environment, 3721 MA Bilthoven, the Netherlands
| | - Jorge Perez
- Medical Microbiology and Infection Control, VU University Medical Center, 1081 BT Amsterdam, the Netherlands
| | - Lucy Baldeón
- Medical Microbiology and Infection Control, VU University Medical Center, 1081 BT Amsterdam, the Netherlands
| | - Abdallah M. Abdallah
- Division of Cell Biology II, Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital (NKI‐AVL), 1066 CX Amsterdam, the Netherlands
- Medical Microbiology and Infection Control, VU University Medical Center, 1081 BT Amsterdam, the Netherlands
| | - Laxmee Caleechurn
- Institut Pasteur Pathogénomique Mycobactérienne Intégrée, 25 Rue du Docteur Roux, 75724 Paris, France
| | - Daria Bottai
- Institut Pasteur Pathogénomique Mycobactérienne Intégrée, 25 Rue du Docteur Roux, 75724 Paris, France
| | - Maaike van Zon
- Division of Cell Biology II, Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital (NKI‐AVL), 1066 CX Amsterdam, the Netherlands
| | - Karin de Punder
- Division of Cell Biology II, Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital (NKI‐AVL), 1066 CX Amsterdam, the Netherlands
| | - Tridia van der Laan
- National Tuberculosis Reference Laboratory, National Institute of Public Health and the Environment, 3721 MA Bilthoven, the Netherlands
| | - Arie Kant
- Department of Bacteriology and TSE's, Central Veterinary Institute, 8203 AA Lelystad, the Netherlands
| | - Ruth Bossers‐de Vries
- Department of Bacteriology and TSE's, Central Veterinary Institute, 8203 AA Lelystad, the Netherlands
| | - Peter Willemsen
- Department of Bacteriology and TSE's, Central Veterinary Institute, 8203 AA Lelystad, the Netherlands
| | - Wilbert Bitter
- Medical Microbiology and Infection Control, VU University Medical Center, 1081 BT Amsterdam, the Netherlands
| | - Dick van Soolingen
- National Tuberculosis Reference Laboratory, National Institute of Public Health and the Environment, 3721 MA Bilthoven, the Netherlands
| | - Roland Brosch
- Institut Pasteur Pathogénomique Mycobactérienne Intégrée, 25 Rue du Docteur Roux, 75724 Paris, France
| | - Nicole van der Wel
- Division of Cell Biology II, Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital (NKI‐AVL), 1066 CX Amsterdam, the Netherlands
| | - Peter J. Peters
- Division of Cell Biology II, Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital (NKI‐AVL), 1066 CX Amsterdam, the Netherlands
- Kavli Institute of Nanoscience, Delft University of Technology, 2628 CJ Delft, the Netherlands
| |
Collapse
|
3
|
Beignon A, Mollier K, Liard C, Munier S, Riviere J, Coutant F, Boulay A, Caleechurn L, Souque P, Bauche C, Charneau P. P17-20. Lentiviral vector-based vaccine against SIV infection and simian AIDS. Retrovirology 2009. [PMCID: PMC2767807 DOI: 10.1186/1742-4690-6-s3-p302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
4
|
Hong H, Coutanceau E, Leclerc M, Caleechurn L, Leadlay PF, Demangel C. Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs. PLoS Negl Trop Dis 2008; 2:e325. [PMID: 18941518 PMCID: PMC2565835 DOI: 10.1371/journal.pntd.0000325] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2008] [Accepted: 09/26/2008] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Buruli ulcer (BU) is a progressive disease of subcutaneous tissues caused by Mycobacterium ulcerans. The pathology of BU lesions is associated with the local production of a diffusible substance, mycolactone, with cytocidal and immunosuppressive properties. The defective inflammatory responses in BU lesions reflect these biological properties of the toxin. However, whether mycolactone diffuses from infected tissues and suppresses IFN-gamma responses in BU patients remains unclear. METHODOLOGY/PRINCIPAL FINDINGS Here we have investigated the pharmacodistribution of mycolactone following injection in animal models by tracing a radiolabeled form of the toxin, and by directly quantifying mycolactone in lipid extracts from internal organs and cell subpopulations. We show that subcutaneously delivered mycolactone diffused into mouse peripheral blood and accumulated in internal organs with a particular tropism for the spleen. When mice were infected subcutaneously with M. ulcerans, this led to a comparable pattern of distribution of mycolactone. No evidence that mycolactone circulated in blood serum during infection could be demonstrated. However, structurally intact toxin was identified in the mononuclear cells of blood, lymph nodes and spleen several weeks before ulcerative lesions appear. Importantly, diffusion of mycolactone into the blood of M. ulcerans-infected mice coincided with alterations in the functions of circulating lymphocytes. CONCLUSION In addition to providing the first evidence that mycolactone diffuses beyond the site of M. ulcerans infection, our results support the hypothesis that the toxin exerts immunosuppressive effects at the systemic level. Furthermore, they suggest that assays based on mycolactone detection in circulating blood cells may be considered for diagnostic tests of early disease.
Collapse
Affiliation(s)
- Hui Hong
- University of Cambridge, Department of Biochemistry, Cambridge, United Kingdom
| | | | - Marion Leclerc
- Institut Pasteur, UP Pathogénomique Mycobactérienne Intégrée, Paris, France
| | - Laxmee Caleechurn
- Institut Pasteur, UP Pathogénomique Mycobactérienne Intégrée, Paris, France
| | - Peter F. Leadlay
- University of Cambridge, Department of Biochemistry, Cambridge, United Kingdom
| | - Caroline Demangel
- Institut Pasteur, UP Pathogénomique Mycobactérienne Intégrée, Paris, France
- * E-mail:
| |
Collapse
|